目的 分析重組人干擾素α-2b聯(lián)合恩替卡韋對慢性乙型肝炎患者免疫功能的影響。方法 選取2016年1月-2018年1月濟(jì)源市人民醫(yī)院收治的慢性乙型肝炎患者95例為研究對象，根據(jù)入院順序隨機(jī)將其分為對照組和觀察組，對照組49例患者給予恩替卡韋進(jìn)行治療，觀察組46例患者給予重組人干擾素α-2b聯(lián)合恩替卡韋進(jìn)行治療，兩組患者均治療3個月。對比兩組患者的臨床療效、免疫功能變化及不良反應(yīng)情況。結(jié)果 觀察組治療總有效率為89.13%，對照組治療總有效率為77.55%，觀察組顯著高于對照組（P<0.05）。治療前，兩組患者的CD4⁺、CD8⁺、CD4⁺/CD8⁺、C3、C4水平均無統(tǒng)計學(xué)差異；治療后，對照組CD4⁺、CD8⁺、CD4⁺/CD8⁺水平與治療前比較差異不顯著；觀察組患者的CD4⁺、CD4⁺/CD8⁺水平均顯著升高，CD8⁺水平顯著降低（P<0.05）；治療后，兩組C3、C4水平均顯著高于治療前（P<0.05）；且觀察組患者的C3、C4水平均顯著高于對照組（P<0.05）。觀察組不良反應(yīng)總發(fā)生率為23.91%，與對照組不良反應(yīng)總發(fā)生率24.49%比較，差異無統(tǒng)計學(xué)差異。結(jié)論 重組人干擾素α-2b聯(lián)合恩替卡韋治療慢性乙型肝炎的效果顯著，該方法可有效改善患者的免疫功能、且不良反應(yīng)未增加，臨床應(yīng)用價值較高。

Objective To analyze the effect of pegylated interferon alfa-2b plus entecavir on immune function in patients with chronic hepatitis B.Methods We selected 95 patients with chronic hepatitis B treated in our hospital between January 2016 and January 2018 as subjects. According to the order of admission, they were randomly divided into a control group of 49 patients (treated with entecavir) and a study group of 46 patients (treated with pegylated interferon alfa-2b plus entecavir). The treatment effect of the two groups of patients was compared.Results The total effective rate of treatment in the study group was (89.13%) significantly higher than that of the control group (77.55%) (P<0.05). Before treatment, there was no significant difference in the levels of CD4⁺, CD8⁺, CD4⁺/CD8⁺, C3, and C4 between the two groups. After treatment, the levels of CD4⁺, CD8⁺, and CD4⁺/CD8⁺ in the study group were significantly lower than those in the treatment group (P<0.05); C3 and C4 levels in study group were significantly lower than before treatment and control group (P<0.05). The incidence of adverse reactions in the study group was 23.91%, and 24.49% in the control group was not statistically different.Conclusions The effect of pegylated interferon alfa-2b combined with entecavir in the treatment of chronic hepatitis B is significant. This method can effectively improve the patient's immune function and does not increase the adverse reactions. The clinical application value is high.